News

Iovance Biotherapeutics: Upcoming Financial Results Conference Call

Iovance Biotherapeutics: Upcoming Financial Results Conference Call

Iovance Biotherapeutics Announces Q3 2024 Earnings Call

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is gearing up to share its third quarter and year-to-date financial results. This well-reputed biotechnology company specializes in pioneering polyclonal tumor infiltrating lymphocyte (TIL) therapies aimed at improving outcomes for cancer patients. Set to take place on the evening of November 7, 2024, at 4:30 p.m. EST, this conference call will provide vital insights into the company's financial health and operational updates.

Details of the Earnings Call

The management team will host a live audio webcast, providing an opportunity for investors and interested parties to engage with the results and receive a comprehensive corporate update. Should you miss the live event, there will be archived access for one year following the presentation. Interested participants can register for the call through the company's investor relations website.

Significant Upcoming Conferences

Alongside the financial call, Iovance will also participate in the prestigious Society for Immunotherapy of Cancer (SITC) 2024 event happening from November 6-10, 2024. These gatherings promise not only exciting discussions but also the unveiling of critical research findings. Notably, on November 8, Iovance is scheduled to present groundbreaking results from its studies on lifileucel, further emphasizing the company's commitment to investigative research in cancer treatment.

Key Presentations at SITC 2024

Distingushing features of Iovance's presentations include:

  • Abstract #409, showcasing multimodal single-cell sequencing analysis that uncovers potential tumor-reactive populations in lifileucel TIL products.
  • A late-breaking report on Abstract #1488 detailing a multicenter Phase 2 trial evaluating lifileucel combined with pembrolizumab for patients with checkpoint inhibitor-naïve metastatic non-small cell lung cancer.
  • Abstract #416 presenting superior anti-tumor activity data for the IL12-engineered TIL IOV-5001.

Stifel Healthcare Conference Appearance

Iovance senior leadership will also be featured in a fireside chat at the Stifel 2024 Healthcare Conference on November 19, 2024. This engagement is anticipated to further highlight the company’s strategic vision and innovations within cell therapy.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is fully dedicated to revolutionizing cancer treatment through its advanced TIL therapies. With a strong focus on harnessing the power of the immune system, the company aims to provide effective solutions for challenging cancer types. Their Amtagvi™ is not only pioneering in the field but has also received FDA approval for a solid tumor indication, marking a critical milestone in innovative cancer therapies.

Company’s Commitment to Innovation

Iovance continues to explore the frontiers of TIL therapy and cell engineering, aiming to enhance and prolong life for cancer patients. Beyond just treatment, their research includes gene-edited cell therapy advancements, putting them at the forefront of medical science.

Contact Information

For more inquiries regarding financial results or corporate communications, you may reach the dedicated team at Iovance:

Iovance Biotherapeutics, Inc.:
Sara Pellegrino, IRC
Senior Vice President, Investor Relations & Corporate Communications
650-260-7120 ext. 264
Sara.Pellegrino@iovance.com

Jen Saunders
Senior Director, Investor Relations & Corporate Communications
267-485-3119
Jen.Saunders@iovance.com

Frequently Asked Questions

What is the date of Iovance’s Q3 2024 earnings call?

The earnings call is scheduled for November 7, 2024, at 4:30 p.m. EST.

How can I access the earnings call?

The earnings call will be live-streamed and archived for one year. Details for registration will be available on Iovance’s investor relations website.

What key conferences is Iovance participating in?

Iovance is participating in the SITC 2024 from November 6-10 and will present findings from recent studies.

What is Amtagvi™?

Amtagvi™ is the first FDA-approved T cell therapy for a solid tumor indication developed by Iovance.

Who should I contact for more information about Iovance?

For inquiries, you may contact Sara Pellegrino or Jen Saunders using the provided email addresses.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 99

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 301

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 116

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 135

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 165

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 156

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading

Top 5 Most Recently Viewed Articles

US LBM Expands Reach with Strategic Milton Truss Acquisition

Updated Category News Views 423

US LBM Welcomes Milton Truss to Its Family US LBM, a leading distributor of specialty building materials, has made a significant move by acquiring Milton Truss, a well-respected manufacturer specializing in structural building components. This acquisition expands US LBM’s operational capabilities and strengthens its presence in the Southeast, particularly within the...

Continue Reading
US Residential Construction Market Shows Promising Growth Ahead

Updated Category News Views 332

The Future of the US Residential Construction Market The residential construction market in the United States is poised to experience significant growth, with estimates suggesting an increase of USD 242.9 million from 2025 to 2029. As household formation rates rise, there is an unmistakable trend towards building more residential units, coupled with an increasing emphasis...

Continue Reading
Orbital Amplifies Currency Reach with Banking Circle

Updated Category News Views 30

Unpacking Orbital's New Alliance with Banking Circle Today's chat's all about payments—specifically how Orbital's rolling out the red carpet with Banking Circle to ramp up their multi-currency payment interface. The company's stretching its limbs into the Nordics, Central Europe, Switzerland, and Australia. With a suit like this, Orbital's not just dropping coins into...

Continue Reading
Jorge Blanco's Achievement Acknowledged as 2025 CRE Tech Influencer

Updated Category News Views 466

Jorge Blanco Celebrated as a 2025 CRE Tech Influencer Altus Group Limited (TSX: AIF), a leading force in asset and fund intelligence for the commercial real estate sector, is excited to announce that its Chief Commercial Officer, Jorge Blanco, has received recognition as a 2025 CRE Technology Influencer. This accolade comes from a renowned publication dedicated to...

Continue Reading
Investor Concerns Rise for Unicycive Therapeutics (UNCY) Amid Investigation

Updated Category News Views 200

Investigating Securities Concerns at Unicycive Therapeutics In the fast-paced world of pharmaceuticals, investor sentiment can shift dramatically based on the health of the company and news that emerges. Currently, Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is facing scrutiny as Pomerantz LLP has initiated an investigation concerning potential claims on behalf of its...

Continue Reading